

LEGISLATIVE FISCAL OFFICE
Fiscal Note



Fiscal Note On: **HB 1199** HLS 26RS 2096

Bill Text Version: **ENGROSSED**

Opp. Chamb. Action:

Proposed Amd.:

Sub. Bill For.:

Date: May 8, 2026	5:19 PM	Author: JORDAN
Dept./Agy.: LA Department of Insurance		Analyst: Cristian Nedelea
Subject: Coverage for genetic testing and the treatment of SCN2A		

INSURANCE/HEALTH

EG NO IMPACT See Note

Page 1 of 1

Provides relative to health insurance coverage for genetic testing and the treatment of SCN2A-associated medical conditions

Proposed law defines certain terms such as genetic testing and SCN2A. Proposed law mandates that any health coverage plan contracted for in this state on or after 1/01/2027, shall provide coverage for genetic testing to diagnose SCN2A-associated medical conditions when ordered by a treating physician or advanced practice provider and determined to be medically necessary by the health coverage plan. Proposed law mandates coverage for medically necessary treatment of SCN2A-associated medical conditions, including but not limited to: anti-seizure medications and other pharmacologic therapies; rehabilitative and habilitative services; medically necessary durable medical equipment, assistive technology, and adaptive devices; nutritional, feeding, and gastrointestinal management services; as well as any additional treatment deemed medically necessary by the treating physician or advanced practice provider. Proposed law stipulates that the determination of medical necessity be made by the enrollee's treating physician or advanced practice provider. If coverage is denied then written notification along with denial reason must be provided and denials may be appealed in accordance with existing laws. Proposed law permits the implementation of prior authorization procedures and cost-sharing requirements. Proposed law prohibits any denial of coverage based on disability, developmental status, or pre-existing conditions. The provisions of this legislation do not apply to limited benefit health insurance policies or contracts.

EXPENDITURES	2026-27	2027-28	2028-29	2029-30	2030-31	5 -YEAR TOTAL
State Gen. Fd.	\$0	\$0	\$0	\$0	\$0	\$0
Agy. Self-Gen.	\$0	\$0	\$0	\$0	\$0	\$0
Ded./Other	\$0	\$0	\$0	\$0	\$0	\$0
Federal Funds	\$0	\$0	\$0	\$0	\$0	\$0
Local Funds	\$0	\$0	\$0	\$0	\$0	\$0
Annual Total	\$0	\$0	\$0	\$0	\$0	\$0

REVENUES	2026-27	2027-28	2028-29	2029-30	2030-31	5 -YEAR TOTAL
State Gen. Fd.	\$0	\$0	\$0	\$0	\$0	\$0
Agy. Self-Gen.	\$0	\$0	\$0	\$0	\$0	\$0
Ded./Other	\$0	\$0	\$0	\$0	\$0	\$0
Federal Funds	\$0	\$0	\$0	\$0	\$0	\$0
Local Funds	\$0	\$0	\$0	\$0	\$0	\$0
Annual Total	\$0	\$0	\$0	\$0	\$0	\$0

EXPENDITURE EXPLANATION

There is no anticipated direct material effect on governmental expenditures as a result of this measure. The Louisiana Department of Insurance (LDI) reports no SGF defrayal costs as well as no impact to the private insurance industry associated with implementation of the proposed law, as coverage for genetic testing and treatment for SCN2A-associated medical conditions is limited to services deemed medically necessary by the health coverage plan.

REVENUE EXPLANATION

There is no anticipated direct material effect on governmental revenues as a result of this measure.

Senate

Dual Referral Rules

House

13.5.1 >= \$100,000 Annual Fiscal Cost {S & H}

6.8(F)(1) >= \$100,000 SGF Fiscal Cost {H & S}

13.5.2 >= \$500,000 Annual Tax or Fee Change {S & H}

6.8(G) >= \$500,000 Tax or Fee Increase or a Net Fee Decrease {S}

Alan M. Boxberger

Alan M. Boxberger
Legislative Fiscal Officer